Previous close | 416.34 |
Open | 417.62 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 415.54 - 420.50 |
52-week range | 290.87 - 446.29 |
Volume | |
Avg. volume | 2,907 |
Market cap | 1.077B |
Beta (5Y monthly) | 0.35 |
PE ratio (TTM) | 0.44 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Crispr stock is down for the fifth straight week as the top Cathie Wood's holding struggles amid dim expectations for its gene-editing drug.
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $416.03, indicating a +0.09% shift from the previous trading day.
While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.